Literature DB >> 23265702

Deregulation of protein methylation in melanoma.

Katharina Limm1, Corinna Ott, Susanne Wallner, Daniel W Mueller, Peter Oefner, Claus Hellerbrand, Anja-Katrin Bosserhoff.   

Abstract

Loss of methylthioadenosine phosphorylase (MTAP) expression and a concomitant accumulation of 5'-methyl-thioadenosine (MTA) characterise several tumour entities including malignant melanoma. MTA affects cellular signalling, proliferation and migration not only of cancer but also surrounding cells including lymphocytes and stromal fibroblasts. The mode of action of MTA is still not known. Interestingly, MTA is a known potent inhibitor of protein arginine methyltransferases (PRMTs) and is used as a tool in studying activity and impact of PRMTs. This study aimed at analysing PRMTs in melanoma and the potential impact of MTA on tumourigenesis. Our findings demonstrate that expression of PRMT4/CARM1 and PRMT6 is deregulated in melanoma, whereas expression of the remaining PRMTs stays unchanged. General PRMT activity and, consequently, symmetric and asymmetric protein methylation are reduced significantly in melanoma cells and tissues. This is due to a loss of MTAP expression and accumulation of MTA. Reduction of protein methylation by MTA affects cell signalling and leads, for example, to an activation of extracellular signal-regulated kinase (ERK) activity. The effects of endogeneous MTA on PRMTs as presented in this study can strongly support the migratory and invasive phenotype of melanoma cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265702     DOI: 10.1016/j.ejca.2012.11.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

2.  Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Authors:  Yudao Shen; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Kwang-Su Park; Irene Chau; Aiping Dong; Hong Zeng; He Chen; Fanye Meng; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Peter J Brown; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2020-05-14       Impact factor: 7.446

3.  The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization.

Authors:  Jasna Lojk; Sonja Prpar Mihevc; Vladimir Boštjan Bregar; Mojca Pavlin; Boris Rogelj
Journal:  Neurotox Res       Date:  2017-04-25       Impact factor: 3.911

4.  Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.

Authors:  Yudao Shen; Magdalena M Szewczyk; Mohammad S Eram; David Smil; H Ümit Kaniskan; Renato Ferreira de Freitas; Guillermo Senisterra; Fengling Li; Matthieu Schapira; Peter J Brown; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2016-09-15       Impact factor: 7.446

5.  PELP1 oncogenic functions involve alternative splicing via PRMT6.

Authors:  Monica Mann; Yi Zou; Yidong Chen; Darrell Brann; Ratna Vadlamudi
Journal:  Mol Oncol       Date:  2013-12-30       Impact factor: 6.603

6.  Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.

Authors:  Lorna H Mitchell; Allison E Drew; Scott A Ribich; Nathalie Rioux; Kerren K Swinger; Suzanne L Jacques; Trupti Lingaraj; P Ann Boriack-Sjodin; Nigel J Waters; Tim J Wigle; Oscar Moradei; Lei Jin; Tom Riera; Margaret Porter-Scott; Mikel P Moyer; Jesse J Smith; Richard Chesworth; Robert A Copeland
Journal:  ACS Med Chem Lett       Date:  2015-04-06       Impact factor: 4.345

7.  TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells.

Authors:  Thomas Green; Xiaofei Chen; Stephen Ryan; Adam S Asch; Maria J Ruiz-Echevarría
Journal:  Prostate       Date:  2013-07-03       Impact factor: 4.104

8.  Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.

Authors:  Else Driehuis; Arne van Hoeck; Kat Moore; Sigrid Kolders; Hayley E Francies; M Can Gulersonmez; Edwin C A Stigter; Boudewijn Burgering; Veerle Geurts; Ana Gracanin; Gergana Bounova; Folkert H Morsink; Robert Vries; Sylvia Boj; Johan van Es; G Johan A Offerhaus; Onno Kranenburg; Mathew J Garnett; Lodewyk Wessels; Edwin Cuppen; Lodewijk A A Brosens; Hans Clevers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205

9.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

10.  A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.

Authors:  Mohammad S Eram; Yudao Shen; Magdalena Szewczyk; Hong Wu; Guillermo Senisterra; Fengling Li; Kyle V Butler; H Ümit Kaniskan; Brandon A Speed; Carlo Dela Seña; Aiping Dong; Hong Zeng; Matthieu Schapira; Peter J Brown; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  ACS Chem Biol       Date:  2015-12-08       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.